Compare Ralph Lauren Corp (RL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ralph Lauren Corp vs Tango Therapeutics Inc. — how do they compare? Ralph Lauren Corp trades at $387.47 (market cap $22.36B), while Tango Therapeutics Inc. trades at $22.49 (market cap $3.74B). The key difference: Ralph Lauren Corp is far larger — about 6× Tango Therapeutics Inc.'s market cap, and Ralph Lauren Corp pays a 1.07% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ralph Lauren Corp for 84 Days and Tango Therapeutics Inc. for 0 Days on average.
| RL | TNGX | |
|---|---|---|
Market Cap | $22.36B | $3.74B |
Volume | 502,434 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $414.25 | $32.90 |
52-Week Low | $309.29 | $7.50 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $23.42B | $2.76B |
Dividend Yield | 1.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ralph Lauren (RL) trades at $373.75, showing modest daily gains with strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.59 exceeding expectations. Revenue growth accelerated to $7.08 billion in 2025, while net income margin improved to 10.49%. Technical indicators show bullish momentum with the stock trading near pivot point resistance at $375, supported by positive moving average signals.
The outlook remains positive with analyst consensus targeting $456.67, representing 22% upside potential. Key opportunities include expanding global retail presence and luxury brand positioning, while risks involve competitive pressures and potential margin compression from increased marketing investments. Institutional sentiment is strongly bullish with 67% buy ratings among 48 covering analysts.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
